Collegium Pharmaceutical (COLL) Cash & Equivalents Growth (1y) (2015 - 2026)
Powered by 
Analysis
Collegium Pharmaceutical (COLL) Cash & Equivalents Growth (1y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 9.93% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 1.58% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | -14.46% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 14.42% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | -40.42% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | -57.55% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 103.71% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 13.19% |
| 10 | Collegium Pharmaceutical | 753.09 Mn | 603.77 Mn | 110.29 Mn | 10.33% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 10.33% |
| Mar 31, 2026 | 179.28% |
| Dec 31, 2025 | 227.71% |
| Sep 30, 2025 | 285.26% |
| Jun 30, 2025 | -32.13% |
| Mar 31, 2025 | -57.92% |
| Dec 31, 2024 | -70.47% |
| Sep 30, 2024 | -84.93% |
| Jun 30, 2024 | -39.07% |
| Mar 31, 2024 | -15.17% |
| Dec 31, 2023 | 37.57% |
| Sep 30, 2023 | 92.75% |
| Jun 30, 2023 | 131.21% |
| Mar 31, 2023 | 152.56% |
| Dec 31, 2022 | -6.83% |
| Sep 30, 2022 | -30.59% |
| Jun 30, 2022 | -39.48% |
| Mar 31, 2022 | -41.63% |
| Dec 31, 2021 | 7.07% |
| Sep 30, 2021 | 16.82% |